Welcome to our dedicated page for Visionary Holdings SEC filings (Ticker: GV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Visionary Holdings Inc. filings document the company's foreign private issuer reporting, material current reports, shareholder meeting results, and governance actions. The available Form 6-K disclosure records annual general meeting matters, director elections, auditor reappointment, voting participation, and reporting under the Exchange Act for a registrant that files on Form 20-F.
These regulatory documents provide formal records of material developments furnished to the SEC and Nasdaq, including company resolutions, financial-statement audit responsibilities, and public-company reporting obligations for GV common shares.
Visionary Holdings Inc. reports the results of its 2025 annual shareholder and board meetings and outlines a major strategic shift. Shareholders elected a nine-member fourth Board of Directors and reappointed Assentsure PAC as auditor through the 2025–2026 fiscal year. The new board then chose William T. Chai as chairman and filled other key board roles, formed four committees, and appointed a senior management team including CEO Xiyong Hou, Co-CEO Jun Huang, COO Robert Jay Lees, and CFO Katy Liu.
The company states it has completed a strategic transformation to focus on high-end anti-aging medical aesthetics as its core business, with education as a supplement and AI as a key enabler. It plans AI-driven initiatives in medical aesthetics and education, a professional financial services platform in Hong Kong, and cooperation with two Chinese medical technology companies to develop products globally and build an anti-aging and health center in Toronto. Management cautions that forward-looking statements are subject to policy, market, and cooperation risks.
Visionary Holdings Inc. files its annual report for the year ended March 31, 2025, highlighting a severe downturn in its legacy businesses and a major strategic pivot. Tuition revenue fell versus the prior year, while real estate income declined by 50%, driving an overall 2025 revenue drop of 50% and exposing the impact of tighter Canadian international education policies and a weak real estate market.
To respond, the company is shifting from education and real estate into life sciences, including large health and elderly care, anti‑aging and high‑end medical aesthetics, and AI‑driven education services. Management reports over $1 million in life sciences revenue in the year, about 20% of total revenue, and forecasts that this segment could reach tens of millions of Canadian dollars and more than 80% of revenue next year. However, the company discloses multiple material weaknesses in internal control over financial reporting, approximately $1.28 million in accrued unpaid income tax liabilities to be repaid in installments beginning January 1, 2026, significant dependence on new financing, and concentrated voting control held through super‑voting stock, all of which present meaningful operational and governance risks.